The U.S. Food and Drug Administration has approved Gadavist (gadobutrol), a contrast agent for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm247207.htm
